|
1
|
Argiris A, Karamouzis MV, Raben D and
Ferris RL: Head and neck cancer. Lancet. 371:1695–1709. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Argiris A and Eng C: Epidemiology, staging
and screening of head and neck cancer. Cancer Treat Res. 114:15–60.
2003. View Article : Google Scholar
|
|
3
|
Pimenta Amaral TM, Da Silva Freire AR,
Carvalho AL, Pinto CA and Kowalski LP: Predictive factors of occult
metastasis and prognosis of clinical stages I and II squamous cell
carcinoma of the tongue and floor of the mouth. Oral Oncol.
40:780–786. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Minamino N, Kangawa K and Matsuo H:
Neuromedin U-8 and U-25: Novel uterus stimulating and hypertensive
peptides identified in porcine spinal cord. Biochem Biophys Res
Commun. 130:1078–1085. 1985. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Minamino N, Kangawa K and Matsuo H:
Neuromedin U-8 and U-25: Novel uterus stimulating and hypertensive
peptides in porcine spinal cord. Biochem Biophys Res Commun.
130:1078–1085. 1985. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Budhiraja S and Chugh A: Neuromedin U:
Physiology, pharmacology and therapeutic potential. Fundam Clin
Pharmacol. 23:149–157. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yu XH, Cao CQ, Mennicken F, Puma C, Dray
A, O'Donnell D, Ahmad S and Perkins M: Pro-nociceptive effects of
neuromedin U in rat. Neuroscience. 120:467–474. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kojima M, Haruno R, Nakazato M, Date Y,
Murakami N, Hanada R, Matsuo H and Kangawa K: Purification and
identification of neuromedin U as an endogenous ligand for an
orphan receptor GPR66 (FM3). Biochem Biophys Res Commun.
276:435–438. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Nakazato M, Hanada R, Murakami N, Date Y,
Mondal MS, Kojima M, Yoshimatsu H, Kangawa K and Matsukura S:
Central effects of neuromedin U in the regulation of energy
homeostasis. Biochem Biophys Res Commun. 277:191–194. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Niimi M, Murao K and Taminato T: Central
administration of neuromedin U activates neurons in ventrobasal
hypothalamus and brainstem. Endocrine. 16:201–206. 2001. View Article : Google Scholar
|
|
11
|
Funes S, Hedrick JA, Yang SJ, Shan LX,
Bayne M, Monsma FJ and Gustafson EL: Cloning and characterization
of murine neuromedin U receptors. Peptides. 23:1607–1615. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Domin J, Ghatei MA, Chohan P and Bloom SR:
Neuromedin U - a study of its distribution in the rat. Peptides.
8:779–784. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yamashita K, Upadhyay S, Osada M, Hoque
MO, Xiao Y, Mori M, Sato F, Meltzer SJ and Sidransky D:
Pharmacologic unmasking of epigenetically silenced tumor suppressor
genes in esophageal squamous cell carcinoma. Cancer Cell.
2:485–495. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Tokumaru Y, Yamashita K, Osada M, Nomoto
S, Sun DI, Xiao Y, Hoque MO, Westra WH, Califano JA and Sidransky
D: Inverse correlation between cyclin A1 hypermethylation and p53
mutation in head and neck cancer identified by reversal of
epigenetic silencing. Cancer Res. 64:5982–5987. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Alevizos I, Mahadevappa M, Zhang X, Ohyama
H, Kohno Y, Posner M, Gallagher GT, Varvares M, Cohen D, Kim D, et
al: Oral cancer in vivo gene expression profiling assisted by laser
capture microdissection and microarray analysis. Oncogene.
20:6196–6204. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ketterer K, Kong B, Frank D, Giese NA,
Bauer A, Hoheisel J, Korc M, Kleeff J, Michalski CW and Friess H:
Neuromedin U is overexpressed in pancreatic cancer and increases
invasiveness via the hepatocyte growth factor c-Met pathway. Cancer
Lett. 277:72–81. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Shetzline SE, Rallapalli R, Dowd KJ, Zou
S, Nakata Y, Swider CR, Kalota A, Choi JK and Gewirtz AM:
Neuromedin U: A Myb-regulated autocrine growth factor for human
myeloid leukemias. Blood. 104:1833–1840. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wu Y, McRoberts K, Berr SS, Frierson HF
Jr, Conaway M and Theodorescu D: Neuromedin U is regulated by the
metastasis suppressor RhoGDI2 and is a novel promoter of tumor
formation, lung metastasis and cancer cachexia. Oncogene.
26:765–773. 2007. View Article : Google Scholar
|
|
19
|
Harten SK, Esteban MA, Shukla D, Ashcroft
M and Maxwell PH: Inactivation of the von Hippel-Lindau tumour
suppressor gene induces Neuromedin U expression in renal cancer
cells. Mol Cancer. 10:892011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Rani S, Corcoran C, Shiels L, Germano S,
Breslin S, Madden S, McDermott MS, Browne BC, O'Donovan N, Crown J,
et al: Neuromedin U: A candidate biomarker and therapeutic target
to predict and overcome resistance to HER-tyrosine kinase
inhibitors. Cancer Res. 74:3821–3833. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ferlito A, Rinaldo A, Silver CE, Shah JP,
Suárez C, Medina JE, Kowalski LP, Johnson JT, Strome M, Rodrigo JP,
et al: Neck dissection: Then and now. Auris Nasus Larynx.
33:365–374. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Brighton PJ, Szekeres PG and Willars GB:
Neuromedin U and its receptors: Structure, function and
physiological roles. Pharmacol Rev. 56:231–248. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Euer NI, Kaul S, Deissler H, Möbus VJ,
Zeillinger R and Weidle UH: Identification of L1CAM, Jagged2 and
Neuromedin U as ovarian cancer-associated antigens. Oncol Rep.
13:375–387. 2005.PubMed/NCBI
|
|
24
|
Haberal I, Celik H, Göçmen H, Akmansu H,
Yörük M and Ozeri C: Which is important in the evaluation of
metastatic lymph nodes in head and neck cancer: Palpation,
ultrasonography, or computed tomography? Otolaryngol Head Neck
Surg. 130:197–201. 2004. View Article : Google Scholar : PubMed/NCBI
|
